GERMANTOWN, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief Scientific Officer of Neuralstem,
will discuss NSI-566, the Company’s stem cell therapy program, at the Cell and Gene Therapy World at the Hyatt Regency in Miami,
FL. The presentation is scheduled for Wednesday, January 24, 2018 at 4:00pm ET.
Neuralstem’s stem cell therapy product candidate, NSI-566, is a spinal cord-derived neural stem cell line. Neuralstem recently
completed a Phase 2 clinical evaluation of NSI-566 for the treatment of Amyotrophic Lateral Sclerosis (ALS). The Company received
orphan designation by the FDA for NSI-566 in ALS and the molecule has since been evaluated in Phase 1 and Phase 2 safety studies in
30 patients. The data showed that the intraspinal transplantation of the cells was safe and well tolerated.
NSI-566 is also being evaluated for the treatment of paralysis from chronic motor stroke as well as chronic spinal cord injury
(cSCI). Subjects from all three indications are currently in long-term observational follow-up periods to continue to monitor
safety and possible therapeutic benefits.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet
medical need. The Company’s lead development candidate, NSI-189, is a small molecule in clinical development for major
depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1
and Type 2 diabetes, and stroke. NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal
cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based
on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward Looking Information
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by
words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the
Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the three and nine months ended September 30,
2017, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any
obligation to update any forward-looking statements.
Contact:
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com
